Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205
Common abbreviation	SPHK1	SPHK2
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11240, http://www.uniprot.org/uniprot/Q9NYA1	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18859, http://www.uniprot.org/uniprot/Q9NRA0
EC number	http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 dihydrosphingosine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712	http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 dihydrosphingosine + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 + http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
Cofactors	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708 [http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708
Inhibitors	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 (pIC50 4.6) [http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219 (pK i 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041 (pK i 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/22970244?dopt=AbstractPlus]
Selective inhibitors	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6623 (pK i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10217 (pK i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/28406646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10218 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/28231433?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624 (pK i 5) [http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6625 (pK i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus]
Comments	SK1 inhibitors induce its proteasomal degradation [http://www.ncbi.nlm.nih.gov/pubmed/20926375?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus]. SK1 crystal structures confirm that it is dimeric [http://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus]; there is no crystal structure available for SK2.	There is no crystal structure available for SK2.